Moderna shares fell in trading on Thursday, dismissing positive second-quarter financial results that included a revenue beat and a narrowed net loss.
The US biotech company reported that income rose by more than two percent in the quarter, driven largely by a vaccine partnership with the British government that helped the firm surpass its own sales guidance.
Despite the operational improvement, the market reaction was negative, reflecting persistent investor caution regarding the company's long-term commercial trajectory.
The sell-off underscores the difficulty Moderna faces in convincing the market that its current revenue streams are sufficient to sustain growth without a new blockbuster pipeline.
The quarterly results offered some signs that management's turnaround strategy is gaining traction, according to earlier reports.
However, progress remains slow, and the stock's decline suggests that traders are prioritizing future uncertainty over modest current improvements.